Skip to content

EPS (Basic) at other companies

Stryker logo
StrykerSYK
$1.95+14.0%
Boston Scientific logo
Boston ScientificBSX
$0.90+95.7%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$0.07-30.0%
Medtronic logo
MedtronicMDT
$0.98+18.1%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$0.45+463%
IAR
Integra LifeSciencesIART
-$0.06+81.8%

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B+108%
Enterprise value$1.24B+105%
P/S1.6×+0.8×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's EPS (basic)?
Avanos Medical (AVNS) reported EPS (basic) of $0.11 in Q1 2026.
How has Avanos Medical's EPS (basic) changed year-over-year?
Avanos Medical's EPS (basic) decreased by 21.4% year-over-year, from $0.14 to $0.11.
What is the long-term trend for Avanos Medical's EPS (basic)?
Over 3 years (2021 to 2025), Avanos Medical's EPS (basic) has grown at a 123.8% compound annual growth rate (CAGR), from $0.14 to -$1.57.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.